LDHC expression has been detected in different tumor types at varying degrees with frequencies up to 100% in lung adenocarcinoma, 83% in cervical cancer, 76% in high-grade serous ovarian carcinoma (HGSC), 44% in melanoma, and 35% in breast cancer [6, 33, 34]. Here, LDHC is linked to breast cancer.